HomeCompareEPGNF vs GBDC

EPGNF vs GBDC: Dividend Comparison 2026

EPGNF yields 178.57% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPGNF wins by $42.14M in total portfolio value
10 years
EPGNF
EPGNF
● Live price
178.57%
Share price
$1.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.91M
Annual income
$29,936,192.20
Full EPGNF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — EPGNF vs GBDC

📍 EPGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPGNFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPGNF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPGNF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPGNF
Annual income on $10K today (after 15% tax)
$15,178.57/yr
After 10yr DRIP, annual income (after tax)
$25,445,763.37/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, EPGNF beats the other by $11,514,889.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPGNF + GBDC for your $10,000?

EPGNF: 50%GBDC: 50%
100% GBDC50/50100% EPGNF
Portfolio after 10yr
$41.84M
Annual income
$23,162,727.80/yr
Blended yield
55.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

EPGNF
No analyst data
Altman Z
-10.1
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPGNF buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPGNFGBDC
Forward yield178.57%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$62.91M$20.78M
Annual income after 10y$29,936,192.20$16,389,263.41
Total dividends collected$58.90M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: EPGNF vs GBDC ($10,000, DRIP)

YearEPGNF PortfolioEPGNF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$28,557$17,857.14$12,490$1,790.28+$16.1KEPGNF
2$78,215$47,658.78$16,522$3,157.73+$61.7KEPGNF
3$205,683$121,992.76$23,578$5,898.68+$182.1KEPGNF
4$519,899$299,818.53$37,115$11,886.75+$482.8KEPGNF
5$1,264,557$708,265.17$66,136$26,423.57+$1.20MEPGNF
6$2,963,097$1,610,021.03$137,257$66,491.44+$2.83MEPGNF
7$6,696,294$3,525,779.94$341,734$194,868.54+$6.35MEPGNF
8$14,611,669$7,446,634.50$1,050,788$685,133.02+$13.56MEPGNF
9$30,820,422$15,185,936.42$4,099,314$2,974,971.01+$26.72MEPGNF
10$62,914,044$29,936,192.20$20,775,530$16,389,263.41+$42.14MEPGNF

EPGNF vs GBDC: Complete Analysis 2026

EPGNFStock

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Full EPGNF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this EPGNF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPGNF vs SCHDEPGNF vs JEPIEPGNF vs OEPGNF vs KOEPGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.